

CURRICULUM VITAE

First name **Michael**

Surname **Mian**

[REDACTED]

[REDACTED]

Citizenship **[REDACTED]**

Work address Division of Hematology and BMT
Azienda Ospedaliera di Bolzano
Via Lorenz Böhler 5
39100 Bolzano
Italy

[REDACTED]

[REDACTED]

[REDACTED]

Mother Language German

Other Languages Italian (writing, reading, listening, spoken interaction and spoken production), English (writing, reading, listening, spoken interaction and spoken production)

EDUCATIONAL BACKGROUND:

November 26th, 2004 Medical Doctor, Medical University of Innsbruck, Austria

February 2nd, 2006 State exam to achieve the „jus practicandi“, Italy

SPECIALITY BOARD:

01.11.2005- 31.10.2009 Resident at the Department of Haematology and CBMT, Hospital of Bolzano, Italy (Head of Department: Prim. Prof. Dr. S. Cortelazzo) via the Università degli Studi di Verona (Head of Department: Prim. Prof. G. Pizzolo)

OTHER ACADEMIC DEGREES AND TITLES:

25.11.2014 Obtainment of the "venia legendi" at the Medical University of Innsbruck, Austria

Since 01.10.2018 Visiting Assistant Professor at the Rīga Stradiņš University RSU)

WORKING EXPERIENCES:

2004	Project assistant in medical biostatistics and informatics at different scientific works
01.02.2005 - 31.07.2005	Resident at the Department of Internal Medicine III of the University of Salzburg (Head of Department: Univ. Prof. Dr. Richard Greil)
02.11.2005 - 31.01.2006	Resident at the Hospital of Bolzano (Urology, Internal Medicine) and at a general practitioner
15.11.2008 - 31.03.2010	Fellowship, Functional Genomics and Lymphoma Group (Dr. Francesco Bertoni), Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland (Prof. Franco Cavalli)
Since 06.04.2010	Senior Staff Member at the Department of Hematology and Center of Bone Marrow Transplantation, General Hospital of Bolzano
09.01.2013 – 29.03.2013	Researcher at the Department of Hematology & Oncology, Medical University of Innsbruck, Austria (Head of Department: Univ. Prof. Dr. Günther Gastl)
01.07.2013-01.07.2014	Scientific Project Collaborator at the Department of Hematology & Oncology, Medical University of Innsbruck, Austria (Head of Department: Univ. Prof. Dr. Günther Gastl)
Since 01.03.2015	Scientific Project Collaborator at the Department of Hematology & Oncology, Medical University of Innsbruck, Austria (Head of Department: Univ. Prof. Dr. Günther Gastl)
Since 01.04.2016	Physician in charge of the simple operative unit "Hämato-onkologisches Ambulatorium" of the Department of Hematology and Center of Bone Marrow Transplantation, General Hospital of Bolzano.
Since 01.10.2018	Visiting Assistant Professor at the Rīga Stradiņš University.

GMP & CELL FACTORY EXPERIENCES:

05/05/2011	Visiting of the Cell Factory of the Istituto Rizzoli, Bologna
10/05/2011	Visiting of the Cell Factory of the Laboratorio Lanzani, Bergamo
24-27/05/2011	Visiting of the Cell Factory of the Cell Factory Terni

PEDAGOGICAL TRAINING:

10.01.2013	Gender Medicine
------------	-----------------

04.02.2013	Presenting Techniques
06.03.2013	Quick-wittedness at work
20.03.2013	Teaching Concepts

TEACHING EXPERIENCE:

April 2013	Lectures for medical students regarding lymphoma & myeloma at the Medical University of Innsbruck.
04.2013 and 04.2016	Prof. a. c. at the Università di Roma – Sapienza by the Claudiana - Scuola Provinciale Superiore di Sanità: Lectures on Immunology, Microbiology and Infectious Diseases (Laurea in Podologia)
16.06.2014	Lecture for nurse students regarding patient education for early discharge after autologous bone marrow transplantation at the University Claudiana of Bolzano
Since 2014	Prof. a. c. at the University of Ferrara by the Claudiana - Scuola Provinciale Superiore di Sanità: Major health issues of systemic nature. (Laurea in infermieristica)
Since 2015	Prof. a. c. at the Università degli Studi di Verona by Claudiana - Scuola Provinciale Superiore di Sanità: Pathophysiology. (Laurea in infermieristica)
2016/2017	Member of the examination board of the Commissione di laurea - CdL Infermieristica polo di Bolzano. I [^] e II [^] sessione 2015/2016

Doctoral Thesis Supervisor & Thesis Reviewer:

2017-2018	Doctoral Thesis Supervisor and Thesis Reviewer: "Retrospektives Lymphomregister Tirol 2010-2015" of Katharina Kaltseis, Medical Student at the University of Innsbruck
2017	Doctoral Thesis Supervisor: "Il piede diabetico" of Stibla Mane, Podiatry Student of the University Sapienza, Rome
2017	PhD Thesis Reviewer: "Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations" of Dr. Patrizia Mondello, PhD Student of the Università degli Studi di Messina Dottorato di ricerca in Biologia Applicata e Medicina Sperimentale

MEMBERSHIPS OF INTERNATIONAL AND NATIONAL RESEARCH GROUPS:

Since 2009	International Extranodal Lymphoma Study Group (IELSG)
Since 2011	European Mantle Cell Network for Phase I/II Trials
Since 2013	Fondazione Italiana Linfomi (FIL)

PRINCIPAL INVESTIGATOR OF TRIALS:

2011	Phase II multicenter clinical trial to investigate the efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib or which are ineligible to both of these drugs. (Protocol #: BDT-01-2011; EudraCT#: 2011-001775-39).
2013	Analisi retrospettiva per valutare l'aumento della sopravvivenza di pazienti affetti da MM con l'introduzione dei nuovi farmaci.
2014	Retrospective, multicenter analysis to compare the feasibility and efficacy of rituximab with bendamustine or CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone) in a real-life setting of patients affected by stage III/IV indolent non-Hodgkin Lymphoma.
2014	Retrospective, multicenter analysis to compare the efficacy and feasibility of Radiotherapy and Rituximab alone or combined together in patients affected by stage I/II follicular lymphoma.
2014	MCL0208: "A Phase III multicenter, Randomized study with Lenalidomide (Revlimid®) maintenance versus observation after Intensified Induction Regimen Containing Rituximab followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation as first line treatment in adult patients with advanced Mantle Cell Lymphoma"; EudraCT number: 2009-012807-25
2014	Retrospective analysis to evaluate efficacy and toxicity of lenalidomide in relapsed or refractory extranodal DLBCL.
2014	Analisi retrospettiva per valutare il decorso clinico di pazienti affetti da linfoma mantellare sottoposti ad una terapia di consolidamento con 90yttrium ibritumomab tiuxetan (Zevalin®) dopo terapia ad alte dosi e trapianto autologo in prima remissione.
2014	Retrospective, multicenter analysis to compare the feasibility and efficacy of rituximab with bendamustine or CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone) in a real-life setting of patients affected by stage III/IV indolent non-Hodgkin Lymphoma.
2015	Retrospective, multicenter analysis to compare the feasibility and efficacy of rituximab-based chemotherapy alone or followed by autologous bone marrow transplantation (ASCT) as second line in Follicular Lymphoma patients who relapsed after Rituximab and bendamustine first-line therapy.

MEMBERSHIPS:

Since 2008	European Hematology Association (EHA)
Since 2009	European Society for Medical Oncology (ESMO)

Since 2009	American Society of Hematology (ASH)
Since 2009	British Society for Haematology (BSH)
Since 2009	Società Italiana di Ematologia (SIE)
Since 2011	American Society of Clinical Oncology (ASCO)
Since 2015	Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie (OeGHO)
Since 2017	Cochrane Member

Reviewer of manuscripts for

- The Lancet Haematology
- Oncotarget
- Clinical Cancer Research
- Hematologica
- European Journal of Haematology
- International Journal of Nanomedicine
- Translational Cancer Research
- Clinical Otolaryngology
- Leukemia Research, Hematological Oncology
- Acta Haematologica
- International Blood Research & Reviews

Member of the Editorial Boards: Memo (ISSN: 1865-5041)

Guest Editor: SPEKTRUM Onkologie, 04/2015 (ISSN: 2223-0645)

LIST of PUBLICATIONS

A) Original Articles (Haematology):

1. Routine clinical use of alemtuzumab in patients with heavily pretreated B-Cell Chronic Lymphocytic Leukemia. A nation-wide retrospective study in Austria. (**Cancer** 2006 Nov; 107(10): 2408-2416) M. Fiegl, A. Falkner, G. Hopfinger, S. Brugger, A. Zabernigg, F. Bauer, F. Haslbauer, D. Demirtas, P. Grossschmidt, G. Tatzreiter, G. Gastl, R. Greil and the Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia (**Mian M.** as a member of the latter)
2. Genome wide DNA-profiling of HIV-related B-cell lymphomas. D. Capello, M. Scandurra, G. Poretti, P. M. V. Rancoita, **M. Mian**, A. Gloghini, C. Deambrogi, M. Martini, D. Rossi, T. C. Greiner, W. C. Chan, M. Ponzoni, S. M. Moreno, M. A. Piris, V. Canzonieri, M. Spina, U. Tirelli, G. Inghirami, A. Rinaldi, E. Zucca, R. D. Favera, F. Cavalli, L. Maria Larocca, I. Kwee, A. Carbone, G. Gaidano, F. Bertoni (**Br J Haematol.** 2010 Jan;148(2):245-55)
3. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. M. Scandurra, D. Rossi, C. Deambrogi, P. MV Rancoita, E. Chigrinova, **M. Mian**, M. Cerri, S. Rasi, E. Sozzi, F. Forconi, M. Ponzoni, S. M. Moreno, M. A. Piris, G. Inghirami, E. Zucca, V. Gattei, A. Rinaldi, I. Kwee, G. Gaidano, F. Bertoni (**Hematol Oncol.** 2010 Jun;28(2):62-7)
4. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. A. Rinaldi, D. Capello, M. Scandurra, T. C. Greiner, W. C. Chan, G. Bhagat, D. Rossi, E. Morra, M. Paulli, A. Rambaldi, P. M. V. Rancoita, G. Inghirami, M. Ponzoni, S. M. Moreno, M. A. Piris, **M. Mian**, E. Chigrinova, E. Zucca, R. Dalla Favera, G. Gaidano, I. Kwee, F. Bertoni (**Br J Haematol.** 2010 May;149(4):569-77)
5. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Marta Scandurra*, **M. Mian* (*equally contributed)**, Timothy C. Greiner, Paola M. V. Rancoita, Cassio P. De Campos, Wing C. Chan, Julie M. Vose, Ekaterina Chigrinova, Giorgio Inghirami, Annalisa Chiappella, Luca Baldini, Maurizio Ponzoni, Andres J.M. Ferreri, Silvia Franceschetti, Gianluca Gaidano, Santiago Montes-Moreno, Miguel A.Piris, Fabio Facchetti, Alessandra Tucci, Josep Fr. Nomdedeu, Thierry Lazure, Olivier Lambotte, Silvia Uccella, Graziella Pinotti, Giancarlo Pruneri, Giovanni Martinelli, Ken H. Young, Maria Grazia Tibiletti, Andrea Rinaldi, Emanuele Zucca, Ivo Kwee and Francesco Bertoni. (**Br J Haematol.** 2010 Nov;151(3):221-31).
6. Patterns of survival of follicular lymphomas at a single institution through three decades. Conconi A, Motta M, Bertoni F, Piona C, Stathis A, Wannesson L, Gracia E, Filho VB, Abreu DR, **Mian M**, Froesch P, Mazzucchelli L, Ghielmini M, Cavalli F, Zucca E. (**Leuk Lymphoma** 2010 Jun;51(6):1028-34).
7. Serotonin receptor 3A expression in normal and neoplastic B cells. Rinaldi A, Chiaravalli AM, **Mian M**, Zucca E, Tibiletti MG, Capella C, Bertoni F. (**Pathobiology** 2010;77(3):129-35).

8. Genome wide DNA-profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Andrea Rinaldi, **Michael Mian**, Ekaterina Chigrinova, Luca Arcaini, Govind Bhagat, Urban Novak, Paola M. V. Rancoita, Cassio P. De Campos, Francesco Forconi, Randy D. Gascoyne, Fabio Facchetti, Maurilio Ponzoni, Silvia Govi, Andrés J.M. Ferreri, Manuela Mollejo, Miguel A. Piris, Luca Baldini, Jean Soulier, Catherine Thieblemont, Vincenzo Canzonieri, Valter Gattei, Roberto Marasca, Silvia Franceschetti, Gianluca Gaidano, Alessandra Tucci, Silvia Uccella, Maria Grazia Tibiletti, Stephan Dirnhofer, Claudio Tripodo, Claudio Doglioni, Riccardo Dalla Favera, Franco Cavalli, Emanuele Zucca, Ivo Kwee, Francesco Bertoni (**Blood**. 2011 Feb 3;117(5):1595-604.)
9. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. Ekaterina Chigrinova, **M. Mian**, Marta Scandurra, Timothy C. Greiner, Wing C. Chan, Julie M. Vose, Giorgio Inghirami, Annalisa Chiappella, Luca Baldini, Maurilio Ponzoni, Andrés J.M. Ferreri, Silvia Franceschetti, Gianluca Gaidano, Alessandra Tucci, Fabio Facchetti, Thierry Lazure, Olivier Lambotte, Santiago Montes-Moreno, Miguel A.Piris, Josep Fr. Nomdedeu, Silvia Uccella, Paola M. V. Rancoita, Ivo Kwee, Emanuele Zucca, Francesco Bertoni. (**Hematol Oncol**. 2011 Mar;29(1):38-41).
10. CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). **M. Mian**, Marcheselli L, Luminari S, Federico M, Cantonetti M, Sarris AH, Rossi A, Rambaldi A, Frontani M, Devizzi L, Gianni AM, Busetto M, Berti E, Martinelli G, Tsang RW, Ferreri AJ, Pinotti G, Pogliani E, Zucca E, Cortelazzo S. (**Ann Hematol**. 2011 Apr;90(4):401-8)
11. High response rate and improvement of long-term survival with combined treatment modalities in poor risk patients with primary thyroid diffuse large B-cell lymphoma: an ILL and IELSG study. **M. Mian**, G. Gaidano, A. Conconi, R. Tsang, M.K. Gospodarowicz, A. Rambaldi, A. Rossi, E. Oldani, M. Federico, S. Luminari, M. Bellei, E.M. Pogliani, F. Rossini, M.E. Cabrera, M. Martelli, A. Lopez-Guillermo, M. Busetto, F. Cavalli, E. Zucca, S. Cortelazzo. (**Leuk Lymphoma**. 2011 May;52(5):823-32)
12. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. **M. Mian**, Scandurra M, Chigrinova E, Shen Y, Inghirami G, Greiner TC, Chan WC, Vose JM, Testoni M, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Uccella S, Tibiletti MG, Zucca E, Kwee I, Bertoni F. (**Ann Oncol**. 2012 Mar;23(3):729-35)
13. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Andrea Rinaldi*, **M. Mian* (*, equally contributed)**, Ivo Kwee*, Davide Rossi, Clara De Ambroggi, Afua Adjeiwaa Mensah, Francesco Forconi, Valeria Spina, Emanuele Cencini, Daniela Drandi, Marco Ladetto, Rita Santachiara, Roberto Marasca, Valter

- Gattei, Franco Cavalli, Emanuele Zucca, Gianluca Gaidano, Francesco Bertoni. (**Br J Haematol.** 2011 Sep;154(5):590-599)
14. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphomas of the Waldeyer's ring in remission after anthracycline-containing chemotherapy. **Mian M**, Ferreri AJ, Rossi A, Conconi A, Tsang R, Gospodarowicz MK, Oldani E, Federico M, Luminari S, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Gutierrez-Garcia G, Busetto M, Cavalli F, Zucca E, Rambaldi A, Cortelazzo S; on behalf of the International Extranodal Lymphoma Study Group (I.E.L.S.G.). (**Leuk. & Lymphoma.** 2013 Jan;54(1):62-8)
 15. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. **Mian M**, Rinaldi A, Mensah AA, Rossi D, Ladetto M, Forconi F, Marasca R, Uhr M, Stussi G, Kwee I, Cavalli F, Gaidano G, Zucca E, Bertoni F. (**Ann Oncol.** 2013 May;24(5):1378-84).
 16. "Idiopathic Bence-Jones proteinuria": a new characterization of an old entity. **Mian M**, Franz I, Wasle I, Herold M, Griesmacher A, Prokop W, Cortelazzo S, Gastl G, Willenbacher W, Gunsilius E, Fiegl M. (**Ann Hematol.** 2013 Sep;92(9):1263-70)
 17. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. F. Zaja, **M. Mian**, S. Volpetti, C. Visco, C. Sissa, I. Nicheli, M. Castelli, A. Ambrosetti, S. Puglisi, R. Fanin, S. Cortelazzo, G. Pizzolo, L. Trentin, F. Rodeghiero, R. Paolini, P. Vivaldi, R. Sancetta, M. Isola, G. Semenzato. (**Am J Hematol.** 2013 Nov;88(11):955-60)
 18. Early-stage diffuse large B-cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study). **M. Mian**, D. Capello, M. B. Ventre, D. Grazio, M. Svaldi, A. Rossi, R. Tsang, M. K. Gospodarowicz, E. Oldani, M. Federico, S. Luminari, L. Marcheselli, E. M. Pogliani, F. Rossini, M. E. Cabrera, M. Martelli, G. Gutierrez-Garcia, M. Busetto, C. Visco, M. Fiegl, D. Rossi, G. Gaidano, F. Cavalli, E. Zucca, A. Rambaldi, S. Cortelazzo on behalf of the International Extranodal Lymphoma Study Group (I.E.L.S.G.) (**Ann Hematol** (2014) 93:221-231)
 19. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Fiegl M, Stauder R, Steurer M, **Mian M**, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL. (**Ann Hematol.** 2014 Feb;93(2):267-77)
 20. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. **Mian M**, Augustin F, Kocher F, Gunsilius E, Willenbacher W, Zabernigg A, Zangerl G, Oexle H, Schreieck S, Schnallinger M, Fiegl M (**Anticancer Res.** 2014 May;34(5):2559-64)
 21. 90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma

- Not Responding Adequately to First-line Treatment. Mondello P, Pifini V, Arrigo C, Derenzini E, **Mian M.** (**Anticancer Res.** 2014 Sep;34(9):5121-5.)
22. A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. **Mian M**, Marcheselli L, Rossi A, Visco C, Chiappella A, Volpetti S, Zaja F, Mondello P, Fiegl M, Billio A, Federico M, Luminari S, Rambaldi A, Cortelazzo S. (**Ann Oncol.** 2014 Dec;25(12):2398-404).
 23. B Cell Lymphoma with Lung Involvement: What Is It about? **Mian M.**, Wasle I., Gritsch S., Willenbacher W., Fiegl M. (**Acta Haematol.** 2014 Nov 4;133(2):221-225)
 24. Radiotherapy for Stage I/II Follicular Lymphoma (FL): Is it Time for A Re-appraisal? Mondello P, Steiner N, Wasle I, Pitini V, **Mian M.** (**Anticancer Res.** 2014 Nov;34(11):6701-4.)
 25. Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. Wasle I, Gamerith G, Kocher F, Mondello P, Jaeger T, Walder A, Auberger J, Melchardt T, Linkesch W, Fiegl M, **Mian M.** (**Ann Hematol.** 2015 Apr;94(4):593-601)
 26. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study. Ninkovic M, Fiegl M, **Mian M.**, Mondello P, Kocher F, Waldthaler C, Verdorfer I, Steurer M, Gastl G, Pircher A. (**Anticancer Res.** 2015 Sep;35(9):5129-39)
 27. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. Ferreri AJ, Donadoni G, Cabras MG, Patti C, **Mian M.**, Zambello R, Tarella C, Di Nicola M, D'Arco AM, Doa G, Bruno-Ventre M, Assanelli A, Foppoli M, Citterio G, Fanni A, Mulè A, Caligaris-Cappio F, Ciceri F. (**J Clin Oncol.** 2015 Nov 20;33(33):3903-10).
 28. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Jackson AE, **Mian M.**, Kalpadakis C, Pangalis GA, Stathis A, Porro E, Conconi A, Cortelazzo S, Gaidano G, Lopez Guillermo A, Johnson PW, Martelli M, Martinelli G, Thieblemont C, McPhail ED, Copie-Bergman C, Pileri SA, Jack A, Campo E, Mazzucchelli L, Ristow K, Habermann TM, Cavalli F, Nowakowski GS, Zucca E. (**Oncologist.** 2015 Oct;20(10):1149-53)
 29. Rituximab im Klinikalltag. **M. Mian.** (**SPEKTRUM Onkologie** 04/2015)
 30. Retrospektive Registeranalysen: Totgeglaubte leben länger? **M. Mian.** (**SPEKTRUM Onkologie** 04/2015)
 31. Register in der Hämatonkologie – ein unverzichtbares Abbild der Realität? Fiegl M., **Mian M.**, Oberaigner W. (**SPEKTRUM Onkologie** 04/2015)
 32. Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? **Mian M.**, Tinelli M., DE March E., Turri G., Meneghini V., Pescosta N., Berno T., Marabese A., Mondello P., Patriarca F., Pizzolo G., Semenzato G., Cortelazzo S., Zambello R. (**Anticancer Res.** 2016 Mar;36(3):1059-65)

33. Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? Mondello P, **Mian M**, Pitini V, Cuzzocrea S, Sindoni A, Galletti M, Mandolino M, Santoro D, Mondello S, Aloisi C, Altavilla G, Benvenga S. (**Curr Oncol.** 2016 Jun;23(3):e165-70.)
34. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? Mondello P, Steiner N, Willenbacher W, Ferrero S, Ghione P, Marabese A, Pitini V, Cuzzocrea S, **Mian M.** (**The Oncologist.** 2016 Sep;21(9):1107-12)
35. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. Mondello P., Steiner N., Willenbacher W., Cerchione C., Nappi D., Mauro E., Ferrero S., Cuzzocrea S., **Mian M.** (**The Oncologist.** Oncologist. 2018 Apr;23(4):454-460)

B) Original Articles (Urology & Oncology):

1. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Mian C, Lodde M, Comploj E, Palermo S, **Mian M**, Maier K, Pycha A. (**Anticancer Res.** 2005 Sep-Oct;25(5):3641-4.)
2. Four years experience in bladder preserving management for muscle invasive bladder cancer. Lodde M, Palermo S, Comploj E, Signorello D, Mian C, Lusuardi L, Longhi E, Zanon P, **Mian M**, Pycha A. (**Eur Urol.** 2005 Jun;47(6):773-8; discussion 778-9.)
3. Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7. Mian C, Lodde M, Comploj E, Palermo S, Lusuardi L, Marziani F, Chiocchetti A, Spada A, **Mian M**, Pycha A. (**Prostate.** 2006 Jun 15;66(9):966-70)
4. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. Mian C, Lodde M, Comploj E, Lusuardi L, Palermo S, **Mian M**, Maier K, Pycha A. (**J Clin Pathol.** 2006 Sep;59(9):984-7)
5. Comparison of complications in three incontinent urinary diversions. A. Pycha, E. Comploj, T. Martini, E. Trenti, C. Mian, L. Lusuardi, M. Lodde, **M. Mian**, S. Palermo. (**Eur. Urol.** 2008 Oct;54(4):825-32)
6. Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours. Mian C, Mazzoleni G, Vikoler S, Martini T, Knüchel-Clark R, Zaak D, Lazica A, Roth S, **Mian M**, Pycha A. (**Eur Urol.** 2010 Aug;58(2):288-92.)
7. Single- vs. Two-Stage Fowler-Stephens Orchidopexy: Are Two Operations Better than One? A Retrospective, Single-Institution Critical Analysis. E. Comploj, **M. Mian**, M. Koen, C. Berger, T. Becker, M. Riccabona (**Curr Urology** 2011;5:12-17)

8. Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy. Lodde M, Lacombe L, Naselli A, Puppo P, Mian M, Fradet Y. (**World J Urol.** 2012 Jan 24)
9. Docetaxel in the Treatment of Non-small Cell Lung Cancer (NSCLC) - An Observational Study Focusing on Symptom Improvement. Pircher A, Wasle IK, Mian M, Gamerith G, Ulsperger E, Studnicka M, Mohn-Staudner A, Hilbe W, Fiegl M. (**Anticancer Res.** 2013 Sep;33(9):3831-6)
10. Comparison of Complications from Radical Cystectomy between Old-Old versus Oldest-Old Patients. Comploj E, West J, Mian M, Kluth LA, Karl A, Dechet C, Shariat SF, Stief CG, Trenti E, Palermo S, Lodde M, Horninger W, Madersbacher S, Pycha A. (**Urol Int.** 2015;94(1):25-30).
11. Cardiovascular Comorbidities and Events in NSCLC: Often Underestimated but Worth Considering. Kocher F, Fiegl M, Mian M, Hilbe W. (**Clin Lung Cancer.** 2015 Jul;16(4):305-12)

C) Short Reports, Case Reports and Letters:

1. Diffuse large B-cell Lymphoma (DLBCL) as a second, non-clonal lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS): case report and review of the literature. Mian M, Tzankov A, Psenak O, Greil R, Fiegl M. (**Leuk Lymphoma.** 2006 May;47(5):940-3)
2. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R (**Leuk Lymphoma.** 2006 Aug;47(8):1683-5)
3. Syk expression patterns differ among B-cell lymphomas. Ponzoni M, Uccella S, Mian M, Rinaldi A, Facchetti F, Pruneri G, Gaidano G, Capella C, Zucca E, Doglioni C, Bertoni F. (**Leuk Res.** 2010 Sep;34(9):e243-5)
4. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. Andrea Rinaldi, Francesco Forconi, Luca Arcaini, M. Mian, Elena Sozzi, Silvia Zibellini, Luca Baldini, Silvia Franceschetti, Gianluca Gaidano, Roberto Marasca, Manuela Mollejo, Miguel A. Piris, Alessandra Tucci, Fabio Facchetti, Govind Bhagat, Riccardo Dalla Favera, Paola M. V. Rancoita, Emanuele Zucca, Ivo Kwee, Francesco Bertoni (**Br J Haematol.** 2010 Dec;151(5):435-9).
5. Profiling of Diffuse Large B-cell Lymphoma with 7q gain. Ekaterina Chigrinova, M. Mian, Yulei Shen, Timothy C. Greiner, Wing C. Chan, Julie M. Vose, Giorgio Inghirami, Annalisa Chiappella, Luca Baldini, Maurilio Ponzoni, Andrés J.M. Ferreri, Silvia Franceschetti, Gianluca Gaidano, Alessandra Tucci, Fabio Facchetti, Thierry Lazure, Olivier Lambotte, Santiago Montes-Moreno, Miguel A. Piris, Emanuele Zucca, Ivo Kwee, Francesco Bertoni. (**Br J Haematol.** 2011 May;153(4):499-503)

6. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Testoni M, Kwee I, Greiner TC, Montes-Moreno S, Vose J, Chan WC, Chiappella A, Baldini L, Ferreri AJ, Gaidano G, **Mian M**, Zucca E, Bertoni F. (**Br J Haematol**. 2011 Oct;155(2):274-7)
7. Del(13q14.3) length matters: an integrated analysis of genomic, FISH and clinical data in 169 chronic lymphocytic leukemia patients with 13q deletion alone or normal karyotype. **M. Mian**, Andrea Rinaldi, Afua Adjeiwaa Mensah, Davide Rossi, Marco Ladetto, Francesco Forconi, Roberto Marasca, Valter Gattei, Emanuele Zucca, Franco Cavalli, Gianluca Gaidano, Ivo Kwee, Francesco Bertoni. (**Hematol Oncol**. 2012 Mar;30(1):46-9)
8. Anaplastic lymphoma kinase negativity (ALK-) remains the major player in anaplastic large cell lymphoma (ALCL). Ekaterina Chigrinova*, **M. Mian*** (***equally contributed**), Anastasia Aleksandrovna Semenova, Natalya Aleksandrovna Probatova, Galil Shevketovich Osmanov, Nikolay Nikolaevich Tupitsyn, Sergio Cortelazzo, and Irina Vladimirovna Poddubnaya. (**blood**, eLetter June 9 2011, http://bloodjournal.hematologylibrary.org/content/111/12/5496/reply#bloodjournal_el_2204)
9. Osteolytic bone lesions as a rare sign of progression of chronic lymphocytic leukemia without evidence of Richter syndrome. **Mian M**, Cerú S, Billio A, Rosanelli C, Cortelazzo S. (**Leuk Lymphoma**. 2012 May;53(5):993-5).
10. Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow Transplantation. **Mian M.**, Farsad M., Pescosta N., Casini M., Cavattoni I.M, Deola S., Cortelazzo S. (**Ann Hematol**. 2013 Jan;92(1):121-3)
11. Does consolidation radiotherapy provide a better disease control in patients with diffuse large B-cell lymphoma of the Waldeyer's ring? **Mian M.**, A.J.M. Ferreri, S. Cortelazzo. (**Clin Oncol (R Coll Radiol)**. 2013 Jan 9).
12. Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. **Mian M**, Kwee I, Rinaldi A, Ponzoni M, Bhagat G, Rossi D, Arcaini L, Gascoyne RD, Mollejo M, Baldini L, Thieblemont C, Gaidano G, Zucca E, Bertoni F. **Br J Haematol**. 2014 Mar;164(6):896-9.
13. The enhanced international prognostic index: finally a reliable prognosticator for early stage diffuse large B-cell lymphomas? **M. Mian**, Luigi Marcheselli, Andrea Rossi, Carlo Visco, Annalisa Chiappella, Volpetti Stefano, Francesco Zaja, Patrizia Mondello, Michael Fiegl, Sergio Cortelazzo Response to An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. [e-Letter], **Blood** (http://bloodjournal.hematologylibrary.org/content/123/6/837/reply#bloodjournal_el_8735). March 20, 2014. Accessed March 20, 2014.
14. Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. P.

- Mondello P, V. Pitini, C. Arrigo, S. Mondello, **M. Mian**, G. Altavilla. Springerplus. 2014 Mar 5;3:123.
15. Rituximab: How evidence based medicine can change our clinical practice. **Mian M.**, Gritsch S., Wasle I., Zabernigg A., Fiegl M. (**Leuk Lymphoma**. 2014 Jul;55(7):1694-6)
 16. R-CHOP versus R-COMP: Are They Really Equally Effective? **Mian M.**, Wasle I., Gamberith G, Mondello P, Melchardt T, Jäger T, Linkesch W, Fiegl M (**Clin Oncol (R Coll Radiol)**. 2014 Oct;26(10):648-52)
 17. Melioidosis: a rare infectious disease in Europe mimicking a lymphoproliferative disorder. I Wasle, W. Elsaesser, P. Cerkl, **M. Mian**, A. Lang (Oncology Research and Treatment, Oct 2014).
 18. Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? Mondello P., Cuzzocrea S, Pitini V, Aloisi C, **Mian M.** (**Acta Oncol**. 2015 Apr 1:1-3.)
 19. Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? Mondello P, Cuzzocrea S, Pitini V, Aloisi C, **Mian M.** (**Acta Oncol**. 2015 Jun;54(6):953-5)
 20. Phase II Trial To Investigate Efficacy And Safety Of Bendamustine, Dexamethasone And Thalidomide In Relapsed Or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide And Bortezomib. **Mian M.**, Norbert Pescosta, Stefania Badiali, Paola Cristina Cappelletto, Luigi Marcheselli, Stefano Luminari, Francesca Patriarca, Renato Zambello, Patrizia Mondello, Anna Pascarella, Giuseppe Tagariello, Alessandra Marabese, Atto Billio, Sergio Cortelazzo (**BJH** 2018, ahead of print)

D) Review Articles:

1. Development of children after chemotherapy during pregnancy („Entwicklung von Kindern nach Chemotherapie in der Schwangerschaft). **Mian M.** (Invited review; **Spectrum Onkologie**. 2013 Dec: 4:12-15).
2. Cancer Cachexia Syndrome: Pathogenesis, Diagnosis, and New Therapeutic Options. Mondello P1, **Mian M.**, Aloisi C, Famà F, Mondello S, Pitini V. (**Nutr Cancer**. 2014 Dec 16:1-15)
3. Pim kinases in hematological malignancies: where are we now and where are we going? Mondello P, Cuzzocrea S, **Mian M.** (**J Hematol Oncol**. 2014 Dec 10;7(1):95)
4. Changing treatment paradigms in lymphoma: new targets and new drugs. **M. Mian**, A. Chiappella. (memo 2015 2015 Sep. 8:184–188)
5. 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. Mondello P., Cuzzocrea S., Navarra M., **Mian M.** (**Oncotarget**. 2016 Feb 16;7(7):7597-609)

6. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. Mondello P, Cuzzocrea S, Navarra M, **Mian M.** (**Oncotarget**, 2017 Jan 12. doi: 10.18632/oncotarget.14610)

E) Abstracts

1. Bence-Jones proteinuria – Increased Incidence of Transformation to Lymphoproliferative Disorder and Amyloidosis. **Mian M.**, Tzankov A., Greil R., Fiegl M. (**Onkologie** 2004;27(suppl3):1-230) – oral presentation
2. Alemtuzumab Is Effective in Patients with Advanced, Pretreated B-Cell Chronic Lymphocytic Leukemia: A Nationwide Study of Routine Use in Austria. Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Haslbauer F, Andel J, Thaler J, Fridrik M, Bauer F, **Mian M.**, Tatzreiter G, Zojer N, Demirtas D, Postner G, Auberger J, Gastl G, Greil R (**blood (ASH Annual Meeting Abstracts)**, Nov 2005; 106: 2971)
3. Frontline high dose sequential Chemotherapy with rituximab (R-HDS) and autologous stem cell transplantation induces high rates of complete response and prolongs survival in mantle cell lymphoma. Billio A, Magni M, Pintimalli M, **Mian M.**, Rossi A, Zanni M, Tarella C, Boccadoro M, Benedetti F, Pizzolo G, Barbui T, Rambaldi A, Gianni AM, Cortelazzo S (**haematologica reports** 2006; 2(issue 12):September-October 2006) – oral presentation
4. Favourable influence of rituximab with high dose sequential chemotherapy (R-HDS) programs and autologous stem cell transplantation in salvage treatment for patients with refractory or relapsed B-cell Non-Hodgkin's-Lymphoma. Pintimalli M, **Mian M.**, Sorio M, Benedetti F, Pizzolo G, Billio A, Barbui T, Rambaldi A, Cortelazzo S (**haematologica reports** 2006; (issue12):September-October 2006) – poster
5. The UCYT+ Test: an update. Mian C, Lodde M, Comploj E, Palermo S, **Mian M.**, Marziani F, Longhi E, Lusuardi L, Pycha A. (**European Urology Supplements** 4 (2005) No. 3, pp. 159 – Abstract 627) – oral presentation
6. Can the provision test improve the prostate cancer staging? Pycha A., Lodde M., Mian C., Comploj E., Palermo S., **Mian M.**, Marziani F., Signorello D., Lusuardi L. (**Eur Urol** 4(3), 68, 2005) - oral presentation
7. Molecular biological analysis of the heterogeneous prostate cancer Gleason score. Mian C., Marziani F., Lodde M., Comploj E., Lusuardi L., **Mian M.**, Pycha A. (**Eur Urol** 5 (2): 99, 2006) - oral presentation
8. Multicolor-FISH for the risk stratification of superficial bladder cancer. Pycha A., Lodde M., Comploj E., Lusuardi L., Palermo, S., **Mian M.**, Maier K., Mian C. (**Eur Urol** 5 (2): 254, 2006) - oral presentation
9. Favourable influence of rituximab with high dose sequential chemotherapy (R-HDS) Programs and autologous stem cell transplantation (ASCT) in salvage treatment for

- patients with refractory or relapsed B-cell Non Hodgkin's Lymphoma. Pintimalli M., **Mian M.**, Rossi A., Sorio M., Pizzolo G., Billio A., Barbui T., Rambaldi A., Cortelazzo S. (**blood (ASH Annual Meeting Abstracts)**; 108(11): 2744, 2006) – poster #922-11
10. Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and autologous stem cell transplantation induces high rates of complete response and prolongs survival in mantle cell lymphoma (MCL). S. Cortelazzo, M. Magni, M. Pintimalli, **M. Mian**, A. Rossi, A. Billio, M. Marchesi, M. Zanni, C. Tarella, M. Boccadoro, A. Andreini, F. Benedetti, G. Pizzolo, T. Barbui, A. M. Gianni. (**blood (ASH Annual Meeting Abstracts)**; 108(11): 3045, 2006) – poster #274-III
 11. Outcome of adult AML at first relapse following a risk-oriented strategy: The Northern Italy Leukemia Group (NILG) Experience. I. M. Cavattoni, E. Morello, **M. Mian**, E. Oldani, T. Intermesoli, E. Borlenghi, G. Rossi, C. Minotto, E. Terruzzi, E. M. Pogliani, E. Audisio, F. Marmont, A. Rambaldi, R. Bassan, S. Cortelazzo. (**blood (ASH Annual Meeting Abstracts)**; 108(11): 5380, 2006)
 12. Primary extranodal Diffuse Large B-cell Lymphoma (DLBCL) arising in distinct sites of head and neck have different clinical characteristics and outcome. S. Cortelazzo, **M. Mian**, A. Oldani, M.E. Cabrera, M. Federico, M. Bellei, S. Magrini, M. Buglione, M. Martelli, H. Gomez, A. Lopez-Guillermo, E. Pogliani, F. Rossini, G. Gaidano, A. Conconi, M. Busetto, C. Visco, R. Tsang, E. Zucca, A. Rambaldi, F. Cavalli. (**haematologica** 92(suppl. No. 1): 0863, 2007) – oral presentation
 13. Long-Term survival of a broad age population of patients with mantle cell lymphoma after frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation. S. Cortelazzo, A. Billio, M. Magni, A. Rossi, M. Pintimalli, M. Marchesi, M. Zanni, **M. Mian**, C. Tarella, M. Boccadoro, A. Andreini, F. Benedetti, G. Pizzolo, M. Gianni, A. Rambaldi. (**haematologica** 92(suppl. No. 1): 0863, 2007)
 14. Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and autologous stem cell transplantation induces a high rate of long-term remissions in patients with mantle cell lymphoma. S. Cortelazzo, M. Magni, C. Tarella, **M. Mian**, A. Billio, A. Rossi, M. Marchesi, A. Gallamini, P. Corradini, F. Ciceri, G. Parvis, I. Majolino, C. Patti, S. Mirto, F. Benedetti, G. Pizzolo, A. M. Gianni, A. Rambaldi (**blood (ASH Annual Meeting Abstracts)**; 110 (11): 1282, 2007) – poster #436-I
 15. Primary Thyroid Lymphoma: a retrospective IELSG and IIL analysis of clinical characteristics, prognostic factors, treatment outcome and somatic hypermutation for localized Diffuse Large B-Cell Lymphoma. S. Cortelazzo, G. Gaidano, **M. Mian**, A. Conconi, A. Rossi, M.E. Cabrera, M. Federico, M. Bellei, S. Magrini, M. Martelli, H. Gomez, A. Lopez-Guillermo, E. M. Pogliani, F. Rossini, M. Busetto, C. Visco, R. Tsang, E. Zucca, A. Rambaldi, F. Cavalli. (**blood (ASH Annual Meeting Abstracts)**; 110(11): 3432, 2007) – poster
 16. The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study). Cortelazzo S, **M. Mian**,

- Cantonetti M, Sarris A, Rossi A, Rambaldi A, Lombardo G, Pasini F, Ambrosetti A, Devizzi L, Busetto M, Bairey O, Berti E, Martinelli G, Tsang R, Rudoy S, Blum R, Ferreri AJM, Pinotti G, Pogliani E, Zucca E. (**blood (ASH Annual Meeting Abstracts)**); 112: 1234, 2008).
17. Prolonged Survival In Refractory/Relapsed Mantle Cell Lymphoma Following an Early-Intensified Chemotherapy With Multiple Autologous Hematopoietic Stem Cell Support. S. Cortelazzo, **M. Mian**, C. Tarella, A. Rossi, M. Magni, A.M. Gianni, C. Patti, S. Mirto, F. Benedetti, G. Pizzolo, A. Rambaldi (**haematologica (13th Congress of EHA)** 93(suppl. no. 1): 0260; 2008 – poster)
 18. Primary Extranodal Follicular Lymphoma Of Head And Neck (PEFLHN): A Rare Disease With A Poor Clinical Outcome (IELSG 23). S. Cortelazzo, **M. Mian**, R. Tsang, A. Rossi, M. E. Cabrera, M. Federico, E. Zucca, M. Busetto, A. Rambaldi, F. Cavalli. (**haematologica (13th Congress of EHA)** 93(suppl. no. 1): 0260; 2008 – poster)
 19. L'efficacia diagnostica del test uCYT+ nella diagnosi e nel follow up del carcinoma in situ della vescica. C. Mian, M. Lodde, E. Comploj, S. Palermo, **M. Mian**, K. Maier, G. Negri, E. Egarter-Viegl, E. Longhi, A. Pycha (**Pathologica** 96(4), 2008)
 20. Combination of clinical and genomic data to study lymphoma pathogenesis. C. P. de Campos, M. Scandurra, **M. Mian**, P. M. V. Rancoita, E. Chigrinova, A. Rinaldi, E. Zucca, I. Kwee, F. Bertoni. (**Workshop of Statistical advances in Genome-scale Data Analysis 2009** - poster)
 21. CLIPI: A new prognostic index for indolent cutaneous B-cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). **M. Mian**, S. Cortelazzo, M. Federico, S. Luminari, L. Marcheselli, M. Cantonetti, A. H. Sarris, A. Rossi, A. Rambaldi, G. Lombardo, M. Frontoni, F. Pasini, L. Devizzi, O. Bairey, M. Busetto, E. Berti, G. Martinelli, R. Tsang, S. Rudoy, R. Blum, A. Ferreri, G. Pinotti, E. Pogliani, E. Zucca (**haematologica (14th Congress of EHA)** 94(suppl. no. 2): 0402; 2009 – poster)
 22. Treatment, Prognostic Factors and Biological Characteristics of Primary Thyroid B-CELL Lymphomas (PTL): an IELSG and ILL study. **M. Mian**, S. Cortelazzo, G. Gaidano, A. Conconi, R. Tsang, M. K. Gospodarowicz, A. Rambaldi, A. Rossi, E. Oldani, M. Federico, S. Luminari, M. Bellei, E. Pogliani, F. Rossini, M.E. Cabrera, H. Garcia, K. Pena, M.B. Martelli, A. Lopez-Guillermo, M. Busetto, F. Cavalli, E. Zucca (**haematologica (SIE 2009)** 94(suppl. no. 2): 0402; 2009 – poster)
 23. Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP. Scandurra M, **Mian M**, De Campos C.P., Rancoita P.M.V., Greiner T.C., Chan W.C., Vose J.M., Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri A. JM, Moreno S.M., Piris M.A., Franceschetti S., Gaidano G, Facchetti F, Tucci A, Lazure T, Lambotte O, Uccella S, Tibiletti M.G., Pinotti G, Pruneri G, Martinelli G, Nomdedeu J.F., Chigrinova E, Rinaldi A, Zucca E, Kwee I, Bertoni F. (**Blood (ASH Annual Meeting Abstracts)**, Nov 2009; 114: 3957. - poster)

24. Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism? Rinaldi A, **Mian M**, Rossi D, Forconi F, Deambrogi C, Spina V, Cencini E, Sozzi E, Drandi D, Ladetto M, Santachiara R, Marasca R, Chigrinova E, Cavalli F, Gattei V, Zucca E, Gaidano G, Kwee I, Bertoni F. (**Blood (ASH Annual Meeting Abstracts)**, Nov 2009; 114: 672. - oral presentation)
25. SNP-Arrays Provide New Insights Into the Pathogenesis of Post-Transplant Diffuse Large B-Cell Lymphoma (PT-DLBCL). Rinaldi A, Capello D, Scandurra M, Greiner TC, Chan WC, Rossi D, Bhagat G, Paulli M, Inghirami G, Ponzoni M, Moreno SM, Piris MA, **Mian M**, Rancoita PMV, Zucca E, Dalla-Favera R, Gaidano G, Kwee G, Bertoni F. (**Blood (ASH Annual Meeting Abstracts)**, Nov 2009; 114: 444. - oral presentation)
26. High Resolution Array-CGH Provides New Insights Into the Prognosis of Chronic Lymphocytic Leukemia (CLL): Is 8p Loss Worse Than 17p Loss? Rinaldi A, **Mian M**, Rossi D, Forconi F, Deambrogi C, Spina V, Cencini E, Sozzi E, Drandi D, Ladetto M, Santachiara R, Marasca R, Chigrinova E, Cavalli F, Gattei V, Zucca E, Gaidano G, Kwee I, Bertoni F. (**Blood (ASH Annual Meeting Abstracts)**, Nov 2009; 114: 2339. - poster)
27. High-resolution genomic profiling of 532 B-cell lymphomas defines distinct tumor signatures, genomic aberrations correlated with outcome and pathogenetic subgroups. Ivo Kwee, Cassio P. De Campos, **M. Mian**, Paola M. V. Rancoita, Andrea Rinaldi, Michela Boi, Marta Scandurra, Tim C. Greiner, Wing C. Chan, Davide Rossi, Gianluca Gaidano, Antonino Carbone, Govind Bhagat, Luca Arcaini, Luca Baldini, Maurilio Ponzoni, Giorgio Inghirami, Miguel A. Piris, Riccardo Dalla Favera, Emanuele Zucca, Franco Cavalli, Francesco Bertoni. (**Second AACR Dead Sea International Conference** on Advances in Clinical Research, March 2010, B59 - poster)
28. The role of del (13q14.3) in diffuse large B-cell lymphomas. **M. Mian**, M. Scandurra, E. Chigrinova, W.C. Chan, G. Inghirami, L. Baldini, M. Ponzoni, G. Gaidano, I. Kwee, F. Bertoni (**35th ESMO congress**; Oct. 2010; 1139PD - poster (**best poster award**)).
29. Bone marrow involvement and 7q gain in diffuse large B-cell lymphoma: a combination of clinical and molecular data. E. Chigrinova **M. Mian**, M. Scandurra, T.C. Greiner, G. Inghirami, L. Baldini, M. Ponzoni, G. Gaidano, I. Kwee, F. Bertoni. (**35th ESMO congress**; Oct. 2010; 1140PD - poster).
30. Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. Annalisa Chiappella, Benedetta Puccini, Simone Ferrero, Luca Arcaini, Ileana Baldi, Giulia Benevolo, Carola Boccomini, Barbara Botto, Chiara Ciocchetto, Sergio Cortelazzo, Alberto Fabbri, Chiara Frairia, Cristina Gabutti, Marco Ladetto, **M. Mian**, Domenico Novero, Lorella Orsucci, Patrizia Pregno, Giorgio Priolo, Luigi Rigacci, Marianna Rossi, Chiara

- Rusconi, Umberto Vitolo. (**Blood (ASH Annual Meeting Abstracts)**, Nov 2010; 116: 1784 - poster).
31. SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. Andrea Rinaldi, **M. Mian**, Ivo Kwee, Clara Deambrogi, Davide Rossi, Francesco Forconi, Afua Adjeiwaa Mensah, Valeria Romina Spina, Elisa Sozzi, Daniela Drandi, Marco Ladetto, Rossana Maffei, Roberto Marasca, Valter Gattei, Franco Cavalli, Emanuele Zucca, Gianluca Gaidano, Francesco Bertoni. (**Blood (ASH Annual Meeting Abstracts)**, Nov 2010; 116: 3611).
 32. Del(13q14.3) length matters: an integrated analysis of genomic, FISH and clinical data in 169 chronic lymphocytic leukemia (CLL) patients with 13q deletion alone or normal karyotype. **M. Mian**, A. Rinaldi, A. A. Mensah, D. Rossi, M. Ladetto, F. Forconi, R. Marasca, V. Gattei, E. Zucca, F. Cavalli, G. Gaidano, F. Bertoni. (**Ann. Oncol.** Volume 22 suppl 4 June 2011: 199 - poster; 11th International Conference on Malignant Lymphoma, Lugano, CH).
 33. Bendamustine in Chronic Lymphocytic Leukemia (CLL): Outcome According to Different Clinical and Biological Prognostic Factors in Everyday Practice. F. Zaja, **M. Mian**, C.Visco, C. Sissa, I. Nichele, M. Castelli, A. Ambrosetti, S. Puglisi, R. Fanin, S. Cortelazzo, G. Pizzolo, L. Trentin, F. Rodeghiero, R. Paolini, P. Vivaldi, R. Sancetta, G. Semenzato. (**Blood (ASH Annual Meeting Abstracts)**, 2012; 3922 - poster)
 34. Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH. **M. Mian**, A. Rinaldi, A. A. Mensah, D. Rossi, M. Ladetto, F. Forconi, R. Marasca, M. Uhr, G. Stussi, I. Kwee, F. Cavalli, G. Gaidano, E. Zucca, F. Bertoni. (**Blood (ASH Annual Meeting Abstracts)**, 2012; 3906 - poster)
 35. Feasibility and efficacy of high doses of antimetabolites followed by high-dose sequential chemoimmunotherapy (R-HDS) and autologous stem cell transplant (ASCT) in patients (pts) with systemic B-cell lymphoma (BCL) and central nervous system (CNS) involvement: A multicenter phase II trial. A. J.M. Ferreri, G. Donadoni, M. G. Cabras, C. Patti, **M. Mian**, R. Zambello, C. Tarella, M. A. Di Nicola, A. D'Arco, M. B. Ventre, M. Foppoli, A. Fanni, G. Doa, A. Mulè, F. Caligaris-Cappio, F. Ciceri. (**J Clin Oncol** 32:5s, 2014 (suppl; abstr 8577) - poster).
 36. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. **M.Mian**, N. Pescosta, S. Luminari, S. Badiali, L. Marcheselli, F. Patriarca, R. Zambello, P. Mondello, A. Pascarella, A. Marabese, V. Pitini, S. Cortelazzo (**EHA 19th annual meeting**, Abstract P1007 – poster)
 37. Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a reappraisal? P. Mondello, G. Altavilla, N. Steiner, I. Wasle, V. Pitini, **M. Mian** (**ESMO 2014**, Abstract 9450 – oral presentation)

38. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) of the Salivary Gland Is Associated with Improved Prognosis When Arising in a Background of Sjögren's Disease and May Not Benefit from Local Therapy. Amie E Jackson, **M. Mian**, Christina H. Kalpadakis, Gerassimos A Pangalis, Anastasios Stathis, Elena Porro, Ellen D McPhail, Thomas M Habermann, Kay M. Ristow, Franco Cavalli, Grzegorz S. Nowakowski, Emanuele Zucca. (**Blood (ASH Annual Meeting Abstracts)**, 2012; 1637 - poster)
39. High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial. Andrés J.M. Ferreri, Giovanni Donadoni, Maria Giuseppina Cabras, Caterina Patti, **M. Mian**, Renato Zambello, Corrado Tarella, Massimo Di Nicola, Alfonso D'Arco, Gianluca Doa, Marta Bruno-Ventre, Marco Foppoli, Alessandro Fanni, Antonino Mulè, Fabio Ciceri, Federico Caligaris-Cappio. (**Blood (ASH Annual Meeting Abstracts)**, 2012; 1724 - poster)
40. High Dose Sequential Chemotherapy with Rituximab and ASCT as First Line Therapy in Adult MCL Patients: Clinical and Molecular Response of the MCL0208 Trial, a FIL Study. Sergio Cortelazzo, Maurizio Martelli, Marco Ladetto, Simone Ferrero, Giovannino Ciccone, Andrea Evangelista, **M. Mian**, Alice Di Rocco, Annalisa Chiappella, Giuseppe Rossi, Alessandro Re, Pier Luigi Zinzani, Monica Balzarotti, Federica Cavallo, Chiara Rusconi, Manuel Gotti, Luca Arcaini, Marco Gobbi, Maria Gomes, Annalia Molinari, Anna Maria Liberati, Mariagrazia Michieli, Giancarlo Latte, Maria Giuseppina Cabras, Domenico Novero, Marco Paulli, Alberto Zamò, Marco Chilosi, Massimo Federico, Umberto Vitolo (**13-ICML 2015**; Abstract Nr.: 209 – Poster)
41. High Dose Sequential Chemotherapy with Rituximab and ASCT as First Line Therapy in Adult MCL Patients: Clinical and Molecular Response of the MCL0208 Trial, a FIL Study. Sergio Cortelazzo, Maurizio Martelli, Marco Ladetto, Simone Ferrero, Giovannino Ciccone, Andrea Evangelista, **M. Mian**, Alice Di Rocco, Annalisa Chiappella, Giuseppe Rossi, Alessandro Re, Pier Luigi Zinzani, Monica Balzarotti, Federica Cavallo, Chiara Rusconi, Manuel Gotti, Luca Arcaini, Marco Gobbi, Maria Gomes, Annalia Molinari, Anna Maria Liberati, Mariagrazia Michieli, Giancarlo Latte, Maria Giuseppina Cabras, Domenico Novero, Marco Paulli, Alberto Zamò, Marco Chilosi, Massimo Federico, Umberto Vitolo (**20th EHA annual meeting 2015**, Abstract Nr.: S106 – oral presentation)
42. 90Y-ibritumomab-tiuxetan consolidation for advanced stage mantle cell lymphoma after first line autologous stem cell transplantation: Is it time for a step forward? Patrizia Mondello, Normann Steiner, Salvatore Cuzzocrea, Carmela Arrigo, Vincenzo Pitini and **M. Mian** (**18th ECCO - 40th ESMO European Cancer Congress**; Abstract Nr.: 3219 – Poster)
43. Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL). Andrea Rinaldi,

Simone Ferrero, Ivo Kwee, Davide Rossi, Alessio Brusca, Valeria Spina, Fary Diop, Filippo Ballerini, Filippo Gherlinzoni, Fabio Benedetti, **Michael Mian**, Caterina Stelitano, Elisa Doni, Alessandra Flavia Salvi, Sergio Cortelazzo, Marco Ladetto, Gianluca Gaidano, Francesco Bertoni. (**Blood (ASH Annual Meeting Abstracts)**, 2017; 621 - poster)

44. Phase II Study With Obinutuzumab-DHAP In Relapsed/Refractory DLBCL Patients Before Autologous Stem Cell Transplantation: A Study From The Fondazione Italiana Linfomi (Giotto Study). Luigi Rigacci, Benedetta Puccini, Carlo Visco, Roberta Battistini, Luca Arcaini, Manuel Gotti, Maria Chiara Tisi, Lara Mannelli, **Michael Mian**, Maurizio Martelli, Leonardo Flenghi, Samantha Pozzi, Francesca Palombi, Anna Pascarella, Andrea Evangelista, Claudia Peracchio (23rd Congress of EHA, Abstract: PS1034 - poster)
45. Obinutuzumab With DHAP Did Not Impair Peripheral Stem Cell Harvest: Results Of The Phase II Prospective FIL Giotto Trial. Luigi Rigacci, Benedetta Puccini, Carlo Visco, Roberta Battistini, Luca Arcaini, Manuel Gotti, Francesca Elice, Sofia Kovalchuk, **Michael Mian**, Alice Di Rocco, Leonardo Flenghi, Samantha Pozzi, Francesca Palombi, Piera Viero, Andrea Evangelista, Daniela Gioia (23rd Congress of EHA, Abstract: PB2486 - publication)

September 20th 2018, Bolzano

Michael Mian